Oncology outcomes
HDAC2 IHC tracks shorter PSA relapse in prostate cancer
Open access · cc by · source: Europe PMC
In 192 prostate carcinomas, class I HDACs were often strongly expressed; HDAC2 independently predicted shorter PSA relapse and linked to dedifferentiation/proliferation.
Study at a glance
- Design
- Cohort — IHC scoring of HDAC1/2/3 with PSA-relapse follow-up
- N
- N=192 · Prostate carcinomas scored by immunohistochemistry
- Population
- Patients with prostate carcinoma assessed for HDAC expression
- Outcome
- HDAC expression associations with clinicopathology, proliferation, and PSA relapse
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Strong expression was common (HDAC1 69.8%, HDAC2 74%, HDAC3 94.8%). High HDAC1/2 associated with dedifferentiation; strong HDAC expression tracked higher proliferation. HDAC2 was an independent prognostic marker associated with shorter PSA relapse.
Methodology
Authors scored HDAC1/2/3 immunohistochemistry in 192 prostate carcinomas and correlated expression with clinicopathological features, proliferation, and PSA-relapse follow-up.
Limitations
Prognostic IHC is not proof that HDAC inhibitors improve outcomes in this cohort. PSA relapse is a surrogate, not metastasis-free or prostate-cancer–specific survival alone. Isoform differences matter for inhibitor interpretation.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
A 22-marker genomic classifier predicts early metastasis after prostatectomy better than clinical variables alone.
In Mayo radical-prostatectomy men enriched for PSA rise, a 22-marker expression classifier achieved validation AUC 0.75 for early clinical metastasis and was the only significant factor in multivariable models.
Scope note — different layer — single-isoform IHC prognosis for PSA relapse, not a multi-gene metastasis classifier
Limits the claim's scope: a different population, assay, or outcome.
HDAC2 immunohistochemistry independently tracks shorter PSA relapse.
Across 192 prostate carcinomas, class I HDACs were frequently strongly expressed; HDAC2 was an independent prognostic marker associated with shorter PSA relapse and with dedifferentiation/proliferation patterns.
Evidence for the claim as stated.
GC discriminates early metastasis after PSA rise; HDAC2 IHC tracks PSA-relapse timing; integrative subgroups stratify biochemical relapse. Shared “aggressive prostate cancer” language does not make the assays interchangeable.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
GC discriminates early metastasis after PSA rise; HDAC2 IHC tracks PSA-relapse timing; integrative subgroups stratify biochemical relapse. Shared “aggressive prostate cancer” language does not make the assays interchangeable.
Related papers in this topic
Same topic cluster — not a recommendation engine.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
- A 22-gene classifier flags early metastasis after prostatectomy
- Five integrated genomic subgroups track prostate-cancer relapse risk
- Higher tumour EZH2 tracks portal-vein invasion in HCC
- DNA methylation signatures separate HCC from nearby liver